RPL6B Antibody

What is RPL6 and why is it important in research?

RPL6 (ribosomal protein L6) is a crucial component of the 60S ribosomal subunit involved in protein synthesis. RPL6 plays significant roles beyond ribosomal function, including interactions with histone H2A and participation in the DNA damage response under PARP control. RPL6 is recruited to DNA damage sites, making it relevant for studies on cellular stress responses and genomic integrity . Additionally, RPL6 has been implicated in cancer biology, with upregulation observed in multidrug-resistant cancer cells and involvement in protecting gastric cancer cells from drug-mediated apoptosis . This multifunctionality makes RPL6 a valuable target for basic and translational research across multiple disciplines.

How do I select the appropriate RPL6 antibody for my specific experimental needs?

Selection should be based on several critical factors, including the specific application, species reactivity, and antibody format. For applications requiring high specificity in human samples, consider monoclonal antibodies like clone AB01/1E12, which detects a band of approximately 33 kDa in Jurkat cell lysates . For cross-species studies involving human, mouse, and rat samples, polyclonal antibodies like 15387-1-AP or CAB15094 provide broader reactivity . When selecting an antibody, review validation data for your specific application and cell type. For example, the 15387-1-AP antibody has been validated for Western blot applications in HEK-293T, HeLa, HepG2, and Jurkat cells, while for immunofluorescence studies, it has been specifically validated in HepG2 cells . Always check published validations in similar experimental systems to your own before selection.

How should I optimize Western blot protocols for RPL6 detection?

For optimal Western blot detection of RPL6, follow these methodological guidelines: First, identify the appropriate molecular weight range for visualization—RPL6 has a calculated molecular weight of 33 kDa but is typically observed at 34-38 kDa on gels . When using antibody 15387-1-AP, start with a dilution of 1:2000 for standard detection and increase to 1:10000 for high-expressing samples . For CAB15094, begin with 1:500 dilution and adjust based on signal strength .

Sample preparation is critical—use RIPA buffer with protease inhibitors and ensure complete lysis of subcellular compartments since RPL6 is found in multiple cellular locations including cytoplasm, cytosolic ribonucleoprotein granules, and nucleus . For loading controls, consider using antibodies against constitutively expressed proteins like GAPDH or β-actin. When transferring proteins, semi-dry transfer at 15V for 15-20 minutes often yields good results for proteins in this molecular weight range. For troubleshooting weak signals, extend primary antibody incubation to overnight at 4°C and consider using enhanced chemiluminescence detection systems.

What are the critical considerations for immunofluorescence studies using RPL6 antibodies?

When performing immunofluorescence studies with RPL6 antibodies, several methodological factors are essential for success. Begin with fixation optimization—while 4% paraformaldehyde is standard, methanol fixation may better preserve ribosomal epitopes in some cell types. For permeabilization, 0.1-0.3% Triton X-100 is typically effective, but gentler detergents like 0.1% saponin may be preferable for preserving certain subcellular structures.

Antibody dilution is application-specific—start with 1:50-1:200 for CAB15094 and 1:50-1:500 for 15387-1-AP , then optimize based on signal-to-noise ratio. Since RPL6 has multiple cellular localizations (cytoplasm, cytosolic ribonucleoprotein granules, nucleus, and rough endoplasmic reticulum) , include appropriate subcellular markers for colocalization studies. HepG2 cells have been specifically validated as positive controls for immunofluorescence with 15387-1-AP , making them an excellent starting point for protocol optimization. For diminishing background, include a blocking step with 5% BSA or 10% normal serum from the same species as your secondary antibody, and consider including 0.1% Tween-20 in washing buffers to reduce non-specific binding.

How can I validate the specificity of RPL6 antibody detection in my experimental system?

Validating RPL6 antibody specificity requires multiple complementary approaches. First, perform positive and negative control experiments—use cell lines with documented RPL6 expression like HepG2, HeLa, or Jurkat cells as positive controls . For negative controls, you can use RPL6 knockdown cells generated through siRNA or CRISPR technology, which should show significantly reduced signal.

Western blot validation should demonstrate a primary band at the expected molecular weight of 33-38 kDa . Multiple antibodies targeting different epitopes of RPL6 can be used to confirm specificity—if different antibodies show similar patterns, this supports specific detection. For immunostaining applications, perform peptide competition assays where the immunizing peptide is pre-incubated with the antibody, which should abolish specific staining.

For definitive validation in critical applications, consider immunoprecipitation followed by mass spectrometry to confirm that the antibody is indeed capturing RPL6 protein. Additionally, comparison of RNA and protein expression patterns (using RT-qPCR and Western blot) can confirm that detection correlates with actual expression levels. Remember that RPL6 antibody 15387-1-AP has been affinity-purified using antigen-specific methods , which generally enhances specificity.

How can I resolve inconsistent RPL6 detection in different cell types or tissues?

Inconsistent RPL6 detection across different biological samples often stems from methodological variables that can be systematically addressed. First, optimize protein extraction based on sample type—for tissues, consider using more robust lysis buffers containing both ionic and non-ionic detergents, while cultured cells may require gentler conditions. The subcellular distribution of RPL6 across cytoplasm, cytosolic ribonucleoprotein granules, cytosol, and nucleus necessitates extraction protocols that efficiently solubilize all compartments.

Antigen retrieval requirements vary significantly between applications and tissue types. For immunohistochemistry with 15387-1-AP, TE buffer at pH 9.0 is recommended for human liver tissue, although citrate buffer at pH 6.0 provides an alternative approach . Different fixation protocols dramatically affect epitope accessibility—examine your fixation method if detection is inconsistent. For formalin-fixed paraffin-embedded samples, extend antigen retrieval times to ensure complete epitope unmasking.

Consider blocking endogenous peroxidases (for IHC) or endogenous fluorescence (for IF) when working with tissues high in these molecules, such as liver, kidney, or spleen samples. Finally, tissue-specific protein modifications might affect epitope recognition—if detection varies by tissue type, consider using multiple antibodies targeting different RPL6 epitopes to validate your findings.

What are the implications of RPL6 mutations in disease models, and how can antibodies help investigate these mechanisms?

RPL6 mutations have significant implications in disease pathogenesis, particularly in cancer and potentially in ribosomopathies. Research indicates that RPL6 upregulation occurs in multidrug-resistant cancer cells and may protect gastric cancer from drug-mediated apoptosis, while downregulation of RPL6 in gastric cancer models suppresses cell growth and cell cycle progression . Additionally, RPL6 promotes proliferation and tumorigenesis in gallbladder cancer cells through interaction with NSUN2 .

When investigating these mechanisms, antibody-based approaches offer several advantages. Immunoprecipitation using RPL6 antibodies like 15387-1-AP or CAB15094, followed by mass spectrometry, can identify novel interaction partners that may be altered in disease states. For studying RPL6's role in DNA damage response, immunofluorescence co-localization studies can track recruitment to damage sites under PARP control . Chromatin immunoprecipitation (ChIP) assays using anti-RPL6 antibodies can examine potential direct interactions with histone H2A during DNA damage responses.

When investigating RPL6 in ribosomopathies, consider the model described for RPL5 mutations in Diamond-Blackfan anemia —similar approaches may be valuable for RPL6-related disorders. Flow cytometry with RPL6 antibodies can quantify expression levels across different cell populations in heterogeneous samples, potentially identifying cell-specific responses to RPL6 dysfunction in disease models.

How does RPL6 detection compare to other ribosomal proteins in experimental systems?

RPL6 detection presents unique characteristics compared to other ribosomal proteins in experimental systems. First, while many ribosomal proteins show highly conserved expression, RPL6 demonstrates context-dependent variation, particularly in cancer cells where it can be significantly upregulated . This makes standardization of experiments more challenging but offers greater insight into pathological processes.

The subcellular distribution of RPL6 across cytoplasm, nucleus, and specialized structures like postsynaptic density and cytosolic ribonucleoprotein granules is more diverse than many other ribosomal proteins. This necessitates careful consideration of fixation and permeabilization protocols to preserve all relevant compartments. When performing co-immunoprecipitation studies, RPL6 may pull down not only ribosomal components but also interaction partners involved in DNA damage response and cell cycle regulation , requiring more complex analysis than typical ribosomal proteins.

In some experimental systems, distinguishing between free and ribosome-associated RPL6 is crucial. Density gradient centrifugation can separate these populations before immunoblotting. For comparative studies, pair RPL6 antibodies with antibodies against core ribosomal proteins such as RPL5, which has well-documented implications in ribosomopathies like Diamond-Blackfan anemia . This approach provides a more comprehensive understanding of ribosome biology in your experimental system.

How can RPL6 antibodies be used to investigate extra-ribosomal functions in cellular stress responses?

RPL6 has emerged as a multifunctional protein with significant roles beyond protein synthesis, particularly in cellular stress responses. To investigate these functions, researchers can implement several antibody-based methodologies. Begin with stress induction experiments—treat cells with various stressors (UV radiation, chemotherapeutic agents, or nutrient deprivation) and track RPL6 localization changes using immunofluorescence with antibodies like 15387-1-AP (1:50-1:500 dilution) or CAB15094 (1:50-1:200 dilution) .

For investigating RPL6's role in the DNA damage response, perform co-immunoprecipitation with RPL6 antibodies followed by immunoblotting for histone H2A and PARP to confirm their interactions . Time-course experiments can determine the kinetics of RPL6 recruitment to DNA damage sites, providing insight into its position in the repair pathway hierarchy. Proximity ligation assays (PLA) using RPL6 antibodies paired with antibodies against suspected interaction partners can visualize protein-protein interactions in situ with high specificity and sensitivity.

To distinguish ribosomal from extra-ribosomal RPL6 populations, combine polysome profiling with immunoblotting to track RPL6 distribution during stress responses. Chromatin immunoprecipitation (ChIP) using RPL6 antibodies can identify potential DNA binding sites or chromatin associations during specific stress conditions, potentially revealing transcriptional regulatory functions beyond its canonical role in translation.

What methodological approaches can address the contradictory findings on RPL6 function in different cancer types?

Contradictory findings regarding RPL6 function across different cancer models necessitate rigorous methodological approaches to resolve discrepancies. Begin with standardized expression analysis—quantify RPL6 at both mRNA (RT-qPCR) and protein levels (Western blot with antibodies like 15387-1-AP or CAB15094) across a panel of cancer cell lines under identical experimental conditions . This baseline characterization can identify cancer-specific expression patterns that might explain functional differences.

For mechanistic investigations, employ complementary gain-and-loss-of-function studies. Use CRISPR-Cas9 to generate RPL6 knockout cell lines and verify protein loss via Western blot. Conversely, create stable RPL6-overexpressing lines and confirm increased expression. In both systems, assess proliferation, apoptosis resistance, and drug sensitivity to establish cancer-specific phenotypes. The interaction between RPL6 and NSUN2 in gallbladder cancer cells suggests unique binding partners may exist in different cancer types . Perform immunoprecipitation with RPL6 antibodies followed by mass spectrometry to identify cancer-specific interaction networks.

To address potential isoform-specific functions, design primers and antibodies that distinguish between possible RPL6 variants. Western blotting using antibodies with known epitopes can detect potential post-translational modifications that might explain functional differences. Finally, for translational relevance, perform tissue microarray analysis using RPL6 antibodies (IHC dilution 1:50-1:500) across different cancer types, correlating expression with clinical outcomes and therapeutic responses.

How can researchers integrate RPL6 antibody-based techniques with emerging technologies for ribosome research?

Integration of traditional RPL6 antibody applications with cutting-edge technologies offers powerful new research possibilities. First, combine proximity labeling techniques like BioID or APEX2 with RPL6 antibodies for validation—fuse RPL6 to a proximity labeling enzyme, induce biotinylation of neighboring proteins, then confirm specific interactions with anti-RPL6 immunoprecipitation. This approach can map dynamic RPL6 interaction networks during cellular processes like stress response or differentiation.

For spatial transcriptomics integration, perform multiplexed immunofluorescence using RPL6 antibodies (dilution 1:50-1:500) together with RNA fluorescence in situ hybridization (FISH) to correlate RPL6 protein localization with active translation sites of specific transcripts. Single-cell proteomics approaches can be validated using flow cytometry with RPL6 antibodies (0.20 μg per 10^6 cells) to confirm expression patterns identified in high-throughput data.

In vivo imaging techniques can be enhanced using site-specifically labeled RPL6 antibodies conjugated to near-infrared fluorophores or radiotracers, allowing tracking of ribosome biogenesis in animal models of disease. For structural biology applications, use RPL6 antibodies to immunopurify intact ribosomes for cryo-electron microscopy, potentially capturing disease-specific ribosome conformations. Finally, CRISPR-based screens targeting ribosome assembly factors can be validated using Western blot and immunofluorescence with RPL6 antibodies, connecting genetic perturbations with specific effects on ribosome structure and function.

What are the optimal storage conditions for maintaining RPL6 antibody activity long-term?

Long-term maintenance of RPL6 antibody activity requires careful attention to storage conditions. For antibody 15387-1-AP, store at -20°C where it remains stable for one year after shipment . The antibody is provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain stability during freeze-thaw cycles . Unlike some antibodies that require aliquoting, 15387-1-AP in 20μl sizes contains 0.1% BSA and aliquoting is reported as unnecessary for -20°C storage . This formulation provides convenience while preserving activity.

To minimize activity loss, avoid repeated freeze-thaw cycles whenever possible. If multiple uses are anticipated, consider preparing working dilutions fresh each time rather than storing diluted antibody. When handling the antibody, maintain cold chain practices—keep on ice during experiments and return to -20°C promptly after use. For antibodies without specific storage information in the product documentation, follow general best practices: store concentrated stock at -20°C or -80°C and keep working dilutions at 4°C for short periods only (typically 1-2 weeks).

Monitor antibody performance periodically using positive control samples with known RPL6 expression, such as HEK-293T, HeLa, HepG2, or Jurkat cells for Western blot applications . This practice helps identify potential activity loss before it affects experimental results. Always check the manufacturer's expiration date and storage recommendations, as formulations may vary between suppliers.

How should researchers troubleshoot diminished signal intensity in long-term RPL6 antibody studies?

When facing diminished signal intensity in extended studies using RPL6 antibodies, implement a systematic troubleshooting approach. Begin by assessing antibody integrity—run a small aliquot on a dot blot or Western blot using a reliable positive control like HepG2 cells . Compare current signal with previous results using identical experimental conditions. If significant signal reduction is observed, antibody degradation may be the issue.

Next, examine your experimental protocol for potential variables—buffer composition changes, different detection systems, or altered incubation times can all impact signal intensity. For Western blot applications, try increasing primary antibody concentration (e.g., from 1:10000 to 1:2000 for 15387-1-AP) or extending incubation time to overnight at 4°C. For immunofluorescence studies, decrease dilution (e.g., from 1:500 to 1:50) and optimize your detection system by using a more sensitive secondary antibody or signal amplification method.

Sample-related factors should also be considered—protein degradation during storage, reduced expression in later cell passages, or batch-to-batch variation in experimental materials can all contribute to signal loss. If these troubleshooting steps don't resolve the issue, consider obtaining a fresh antibody lot and performing side-by-side comparison with your current reagent to determine if lot-specific factors are involved. For critical long-term studies, creating a master stock of validated antibody stored in single-use aliquots at -80°C can provide consistency throughout the project duration.